Cargando…

Current evidence supporting “letrozole” for ovulation induction

Aromatase inhibitor “letrozole” was first introduced as a potential ovulation induction (OI) drug almost a decade back. Large number of studies has been published using letrozole for OI: In polycystic ovary syndrome (PCOS) women, clomiphene citrate (CC) resistant women, for intrauterine insemination...

Descripción completa

Detalles Bibliográficos
Autor principal: Kar, Sujata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778612/
https://www.ncbi.nlm.nih.gov/pubmed/24082649
http://dx.doi.org/10.4103/0974-1208.117166
_version_ 1782285137267916800
author Kar, Sujata
author_facet Kar, Sujata
author_sort Kar, Sujata
collection PubMed
description Aromatase inhibitor “letrozole” was first introduced as a potential ovulation induction (OI) drug almost a decade back. Large number of studies has been published using letrozole for OI: In polycystic ovary syndrome (PCOS) women, clomiphene citrate (CC) resistant women, for intrauterine insemination and also in various protocols of mild stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Letrozole appears to be a good option, with its oral route of administration, cost, shorter half-life and negligible side effects. However, the verdict on efficacy and safety of letrozole is still uncertain. This review explores the current scientific data supporting letrozole for OI.
format Online
Article
Text
id pubmed-3778612
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37786122013-09-30 Current evidence supporting “letrozole” for ovulation induction Kar, Sujata J Hum Reprod Sci Review Article Aromatase inhibitor “letrozole” was first introduced as a potential ovulation induction (OI) drug almost a decade back. Large number of studies has been published using letrozole for OI: In polycystic ovary syndrome (PCOS) women, clomiphene citrate (CC) resistant women, for intrauterine insemination and also in various protocols of mild stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Letrozole appears to be a good option, with its oral route of administration, cost, shorter half-life and negligible side effects. However, the verdict on efficacy and safety of letrozole is still uncertain. This review explores the current scientific data supporting letrozole for OI. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3778612/ /pubmed/24082649 http://dx.doi.org/10.4103/0974-1208.117166 Text en Copyright: © Journal of Human Reproductive Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kar, Sujata
Current evidence supporting “letrozole” for ovulation induction
title Current evidence supporting “letrozole” for ovulation induction
title_full Current evidence supporting “letrozole” for ovulation induction
title_fullStr Current evidence supporting “letrozole” for ovulation induction
title_full_unstemmed Current evidence supporting “letrozole” for ovulation induction
title_short Current evidence supporting “letrozole” for ovulation induction
title_sort current evidence supporting “letrozole” for ovulation induction
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778612/
https://www.ncbi.nlm.nih.gov/pubmed/24082649
http://dx.doi.org/10.4103/0974-1208.117166
work_keys_str_mv AT karsujata currentevidencesupportingletrozoleforovulationinduction